TOKYO, January 15 /PRNewswire/ --

Kyowa Hakko Kirin Co., Ltd. (Chiyoda-ku, Tokyo Japan; President, Dr. Yuzuru Matsuda) announced on January 15 (Tokyo Time) that it has decided to continue the domestic development of its proprietary anti-Parkinson's disease drug KW-6002 (generic name: Istradefylline) and move it forward with a Phase 3 clinical trial in Japan.

ST. PETERSBURG, Florida, January 15 /PRNewswire/ --

Smith Nephew's Advanced Wound Management division (LSE: SN; NYSE: SNN) announced that on Tuesday, the Specialist Patents Court in the High Court of Justice of England and Wales granted Kinetic Concepts, Inc (NYSE: KCI) a temporary injunction prohibiting Smith Nephew from commercializing foam dressing kits for negative pressure wound therapy in the United Kingdom. The temporary injunction will remain in place until the court can rule on the patent infringement action that KCI filed in the United Kingdom against Smith Nephew in December 2008. An early trial date has been ordered for the next available court date after March 23, 2009 to be confirmed by the Court.

SUWANEE, Georgia, January 15 /PRNewswire/ --

- Classroom technology combines traditional whiteboard surface with interactive performance

PolyVision, a Steelcase company, today introduces eno(TM), a revolutionary new interactive whiteboard. PolyVision's breakthrough solution combines the simplicity and ease of a traditional whiteboard surface with interactive performance -- all without cords, cables or costly installation.

eno is the first three-in-one interactive whiteboard solution -- dry-erase marker, magnetic and multimedia -- giving teachers a flexible, versatile tool that keeps pace with the demands of today's students. It delivers true interactive performance, engaging today's students with high-tech multimedia, multisensory, multidimensional lessons.

HIGH WYCOMBE, England, January 15 /PRNewswire/ --

- Ortho Clinical Diagnostics Introduces Flagship VITROS(R) 5600 Integrated System and High-Capacity VITROS(R) 3600 Immunodiagnostic System

Ortho Clinical Diagnostics today announced commercial availability in Europe(*) for two new clinical laboratory systems, the flagship VITROS(R) 5600 Integrated System and the high-capacity VITROS(R) 3600 Immunodiagnostic System. These next generation diagnostic platforms are uniquely designed based on world-class VITROS(R) technologies to address the needs of the modern clinical laboratory, giving patients and clinicians high-quality and reliable test results.

LONDON, January 15 /PRNewswire/ --

For the first time, scientists can prove that Deeside Mineral Water actually slows the signs of ageing and does so 50% more effectively than other tested waters on the market.

In the first of two new research studies, Deeside Mineral Water was rigorously tested against other major international market leading brands of bottled water. The study was undertaken by scientists at Queen Margaret University in Edinburgh and confirmed that Deeside Mineral Water is 50% more effective than other waters tested in suppressing free radicals.

LONDON, January 15 /PRNewswire/ --

David Pruce, Director of Policy and Communications at the Society commented:

The Society welcomes initiatives relating to greater self care support and believes that the reclassification of certain therapeutic categories of medicines from POM to P can enhance customer choice, convenience and access to medicines.

An ounce of prevention is worth a pound of cure, according to Ben Franklin. But what if the prevention causes more harm than benefit? And what if the prevention doesn't prevent much of anything at all?

LONDON, January 14 /PRNewswire/ -- Yes, it's true - UK children really do prefer the taste of oranges and strawberries over soft-drink flavours like fizzy cola.

That's just one of the findings to be announced at the Formulating Better Medicines for Children conference, the first event of its kind to draw together Europe's experts on the design, manufacture, delivery and thinking behind paediatric medicine.

Hosted by the Royal Pharmaceutical Society of Great Britain (RPSGB), the two-day conference in March will put the spotlight on issues regarding the creation of medicines for children aged 0 to 16, in addition to the step-change in clinical trials involving young people.

LAVAL, Quebec, January 14 /PRNewswire/ -- BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that it will conclude enrolment next month for the Canadian-European pivotal trial of its cartilage repair device, BST-CarGel(R). To date, the Company has enrolled more than 70 subjects and participating clinical sites will be permitted to enrol additional subjects until February 10th, 2009.

PARIS, January 14 /PRNewswire/ -- Kewego, the European leader in management, broadcasting and monetisation solutions for videos on the Internet, intranets and screen networks, announces fundraising of 4.7m Euros subscribed by the company's historic shareholders: Banexi Venture Partners and CDC Entreprises, a subsidiary of Caisse des Depots et Consignations (through the France Investissements team).